



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

SN

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,170	07/16/2003	John Jacob Vander Zanden	3038	2206
7590	11/26/2004		EXAMINER	
WALTER A. HACKLER, Ph.D. PATENT LAW OFFICES SUITE B 2372 S.E. BRISTOL NEWPORT BEACH, CA 92660-0755			GEHMAN, BRYON P	
			ART UNIT	PAPER NUMBER
			3728	
			DATE MAILED: 11/26/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/622,170	ZANDEN ET AL.	
	Examiner	Art Unit	
	Bryon P. Gehman	3728	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 21 June 2004.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-25 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-25 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>7/16/03</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____. |

1. Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 250 words. It is important that the abstract not exceed 250 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

2. The abstract of the disclosure is objected to because in lines 5-6, "with each tablet in set having..." is ungrammatical. Correction is required. See MPEP § 608.01(b).

3. Claim 10 is objected to because of the following informalities: In line 1, "each rows" is ungrammatical. Appropriate correction is required.

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 1-3, 5-6, 8-11 and 13-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Walsh (2004/0176381) in view of Hermelin et al. (6,375,956). Walsh

discloses a package for enabling compliance with a regimen of dosage of medication over a period of time, the package comprising a backing having an array of receivers including columns and rows, a plurality of tablets and indicia disposed adjacent the columns and rows for displaying common days and successive weeks. Hermelin et al. discloses it was known to provide tablets of different dosages at different times in the course of a regimen (see column 10, lines 56-65). To modify the package of Walsh employing tablets of different dosages would have been obvious in view of Hermelin et al., because it was known to employ a controlled variable or pulsed release system in the medication regimen field as disclosed by Hermelin et al..

As to claims 2 and 10, Walsh discloses each row as a successive week and each column as a different day.

As to claims 5 and 14, to provide the alternative of the rows being days and the columns being weeks would have been an obvious modification of Walsh to one of ordinary skill in the art.

6. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Walsh in view of Hermelin et al.. To merely provide the package of the above described combination would have been obvious in order to obtain the package advantages previously described.

7. Claims 4, 7, 12 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over the art as applied to claims 3, 6, 11, 15 and 18 above, and further in

view of Lipton et al. (5,922,773). To employ Memantine to treat glaucoma to reduce damage to retinal ganglion cells was known in the medical field as taught by Lipton et al.. To provide Memantine in a controlled variable or pulsed release system of different dosages would have been obvious in order to ease the patient onto the medication, or reduce the amount necessary as the medication has been applied to wean a person off the medication. The exact amounts of Memantine employed would have been dosages recognized as effective by one of ordinary skill in the art (a medical professional or pharmacist).

8. Claims 18-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Walsh in view of Hermelin et al. and Lipton et al. The prior art combination has been explained above with respect to the package. To employ the package in the expected package manner to treat a patient to reduce damage to the retinal ganglion cells caused by glaucoma would have been obvious in view of Walsh, Hermelin et al. and Lipton et al., taken together.

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Weinstein et al. and Weinstein disclose different dosages of the same medication taken at different times.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bryon P. Gehman whose telephone number is (571)

272-4555. The examiner can normally be reached on Monday through Wednesday from 5:30am to 6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mickey Yu, can be reached on (571) 272-4562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-4555.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Bryon P. Gehman
Primary Examiner
Art Unit 3728

BPG